FGP
AKBA icon

Freestone Grove Partners’s Akebia Therapeutics AKBA Stock Holding History

Freestone Grove Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-202,122
Closed -$552K – 724
2025
Q3 		$552K Buy
+202,122
New +$672K ﹤0.01% 520

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Freestone Grove Partners's AKBA Position: Q4 2025 in Review

Freestone Grove Partners sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 202,122 shares — an estimated $552K sold.

Freestone Grove Partners first reported a position in AKBA in Q3 2025 and held it in 1 quarter. The position peaked at $552K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Freestone Grove Partners reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 202,122 Akebia Therapeutics shares in Q4 2025, an estimated $552K.
  • Freestone Grove Partners first reported a position in Akebia Therapeutics in Q3 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Akebia Therapeutics position peaked at $552K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.